

CITATION REPORT

List of articles citing

Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature

DOI: 10.1016/j.semarthrit.2003.09.012

Seminars in Arthritis and Rheumatism, 2004, 33, 336-51.

Source: <https://exaly.com/paper-pdf/36843530/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Antimalarials. 2005 , 347-372		
115	Chloroquine-induced cardiomyopathy-echocardiographic features. 2005 , 18, 383-7		31
114	Cutaneous Lupus Erythematosus. 2005 ,		11
113	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201		8
112	[Complete auriculoventricular blockage in adult patients with systemic lupus erythematosus. Case series and a review of the literature]. 2006 , 2, 294-7		
111	Modifying toll-like receptor 9 signaling for therapeutic use. 2006 , 6, 287-91		17
110	CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. 2006 , 172, 1057-68		107
109	The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters. <i>Lupus</i> , 2006 , 15, 521-5	2.6	44
108	Neuronal storage disease in a group of captive Humboldt penguins (<i>Spheniscus humboldti</i>). 2006 , 43, 1029-33		10
107	Cardiomyopathy related to antimalarial therapy with illustrative case report. 2007 , 107, 73-80		76
106	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. 2007 , 46, 808-10		90
105	[Complete auriculoventricular block during chloroquine treatment]. 2007 , 28, 134-6		5
104	New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. 2007 , 38, 1858-63		49
103	[Reversible restrictive cardiomyopathy secondary to chloroquine]. 2007 , 129, 157		4
102	Drug-induced cardiovascular disorders. 2007 , 30, 783-804		26
101	A 73-year-old woman with rheumatoid arthritis and shortness of breath. 2008 , 59, 892-9		8
100	The B cell in systemic lupus erythaematosus: a rational target for more effective therapy. 2008 , 67, 1374-81		14

99	Systemic Lupus Erythematosus. 2008 , 303-338	6
98	Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. 2008 , 47, 1476-83	33
97	In utero exposure to chloroquine alters sexual development in the male fetal rat. 2009 , 237, 366-74	3
96	Cardiotoxicity after low-dose chloroquine antimalarial therapy. 2009 , 24, 385-7	14
95	Cardiac pathology of systemic lupus erythematosus. 2009 , 62, 584-92	65
94	New directions in the treatment of systemic lupus erythematosus. 2009 , 25, 1501-14	26
93	[Chloroquine cardiotoxicity in long-term lupus therapy in two patients]. 2009 , 136, 530-5	12
92	Review article: systemic lupus erythematosus: a review for anesthesiologists. 2010 , 111, 665-76	35
91	Hydroxychloroquine-induced myopathy. 2010 , 16, 28-31	26
90	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312	1
89	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8	645
88	Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. 2010 , 36, 53-80, vii-viii	176
87	Acute lupus myocarditis: Clinical features and outcome. <i>Lupus</i> , 2011 , 20, 981-8	2.6 36
86	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29	166
85	Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. 2011 , 364, 1450-60	34
84	SLE in Children. 2011 , 573-597	
83	Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy. 2011 , 19, 482-5	16
82	Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis?. 2012 , 39, 1099-103	20

81	Fatal antimalarial-induced cardiomyopathy: report of 2 cases. 2012 , 18, 363-6	23
80	Evidence for risk of cardiomyopathy with hydroxychloroquine. <i>Lupus</i> , 2012 , 21, 1594-6	2.6 22
79	Hydroxychloroquine-induced oxidative stress on sciatic nerve and muscle tissue of rats: a stereological and biochemical study. 2012 , 31, 1066-73	7
78	Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. 2012 , 12, 305-12	25
77	Comparative safety of therapies in systemic lupus erythematosus. 2012 , 38, 795-807	1
76	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. 2012 , 142, e1S-e111S	37
75	Accelerated atherosclerosis in patients with SLE--mechanisms and management. 2012 , 8, 214-23	167
74	Cardiovascular Involvement in Systemic Lupus Erythematosus. 2012 ,	1
73	Progressive weakness with respiratory failure in a patient with sarcoidosis. 2012 , 69, 534-7	1
72	Chloroquine cardiomyopathy - a review of the literature. 2013 , 35, 434-42	120
71	Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. 2013 , 2, 77-83	92
70	Myopathies due to Systemic Disease. 2013 , 224-238	
69	Lesiones auriculares inducidas por cloroquina: estudio histopatológico. 2013 , 46, 117-121	2
68	Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. <i>Lupus</i> , 2013 , 22, 1070-6	9
67	Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. 2013 , 19, 286-8	60
66	Cardiopulmonary Disease in SLE. 2013 , 352-362	
65	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62	27
64	Rheumatoid arthritis and cardiac disease. 2014 , 9, 457-473	

63	Cardiovascular disease in rheumatoid arthritis. 2014 , 40, 27-49		27
62	Arritmia cardíaca recurrente en un paciente con miocarditis lúpica. 2015 , 36, A129-A130		
61	Miocardopatía dilatada en un paciente con lupus discóide crónico en tratamiento con mepacrina. 2015 , 30, 206-208		
60	Hydroxychloroquine neuromyotoxicity: a case with rapid course and complete recovery. 2015 , 36, 2293-4		5
59	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. 2016 , 134, e579-e646		314
58	Antimalarial myopathy in a systemic lupus erythematosus patient with quadriplegia and seizures: a case-based review. 2017 , 36, 1437-1444		5
57	The Case Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus. 2017 , 92, 271-272		4
56	Hydroxychloroquine in systemic lupus erythematosus (SLE). 2017 , 16, 411-419		153
55	Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. 2017 , 30, 571-575		4
54	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. 2017 , 13, 35-41		21
53	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. 2017 , 617-643		0
52	Sjögren's Syndrome. 2017 , 281-300		
51	Antimalarial-induced cardiomyopathy: a systematic review of the literature. <i>Lupus</i> , 2018 , 27, 591-599	2.6	32
50	Heart failure in systemic lupus erythematosus. 2018 , 28, 187-197		14
49	Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. 2018 , 252, 216-219		20
48	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. 2018 , 41, 919-931		195
47	Hydroxychloroquine - How Much Is Too Much?. 2019 , 46, 340-342		5
46	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. 2020 , 100, 633-672		14

45	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. 2020 , 22, 191	8
44	Treatment Options for COVID-19: A Review. 2020 , 7, 480	46
43	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747	11
42	Cardiological society of India position statement on COVID-19 and heart failure. 2020 , 72, 75-81	13
41	Cardiac effects and toxicity of chloroquine: a short update. 2020 , 56, 106057	23
40	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32	24
39	[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. 2020 , 41, 335-338	3
38	Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?. 2021 , 80, e6	2
37	Sinus node disfunction in an adolescent with systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 342-346	2.6 1
36	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. 2021 , 102, 275-281	7
35	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. 2021 , 87, 1432-1442	26
34	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
33	Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. 2021 , 77, 1717-1727	8
32	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. 2021 , 41, 1189-1202	5
31	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. 2021 , 77, 1513-1521	2
30	A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction. 2021 , 1-14	0
29	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. 2021 , 23, 854-871	29
28	Malaria-induced ptosis. 2021 , 22, 101038	

27	Cardiac manifestations of rheumatic diseases. 2021 , 156, 615-621		2
26	Cardiac manifestations of rheumatic diseases. 2021 , 156, 615-621		
25	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. 2021 , 27, 727-743		7
24	COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection. 2021 , 2,		
23	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. 2021 ,		1
22	Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis. 2021 , 51, 237-245		1
21	Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases. 2021 , 5, 1-10		0
20	Hydroxychloroquine. 2005 , 81-92		5
19	Cardiac Manifestations of Systemic Lupus Erythematosus: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options. 2022 , 30, 38-43		5
18	Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9	12
17	A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19). 2020 , 102, 932-933		18
16	A High Fidelity Transmural Anisotropic Ventricular Tissue Model Function to Investigate the Interaction Mechanisms of Drug: An In-Silico Model for Pharmacotherapy.		
15	Connective Tissue Diseases and the Heart. 2007 , 2331-2356		1
14	Hydroxychloroquine induced dilated cardiomyopathy and lupus mastitis. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	
13	Treatment of non-renal lupus. 2011 , 1307-1316.e4		
12	Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 53, 116523	3.4	1
11	Myeloid bodies is not an uncommon ultrastructural finding.. <i>Ultrastructural Pathology</i> , 2022 , 1-9	1.3	1
10	Antimicrobial agents and torsades de pointes. 2022 , 231-266		

9	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 096120332211156	2.6	○
8	Hydroxychloroquine and Fabry Disease: Three Case Reports Examining an Unexpected Pathologic Link and a Review of the Literature. <i>Case Reports in Rheumatology</i> , 2022 , 2022, 1-6	0.8	○
7	Peimine inhibits variants of SARS-CoV -2 cell entry via blocking the interaction between viral spike protein and ACE2.		○
6	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		○
5	Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia. 2022 ,		○
4	Rapid Onset and Resolution of Hydroxychloroquine Cardiomyopathy: A Case Report. 2022 , 2022, 1-4		○
3	A change of heart.		○
2	Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus. 2023 ,		○
1	Hydroxychloroquine and Cardiotoxicity. Publish Ahead of Print,		○